<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm Tags: donepezil</title>
        <description>MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'donepezil'.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=%22donepezil%22&t=%22donepezil%22&r=Exact&o=d&f=tag]]></link>
        <lastBuildDate>Sat, 03 Sep 2011 02:38:43 +0100</lastBuildDate>
        <item>
            <title>Neuropsychology Abstract of the Day: Donepezil and Aphasia</title>
            <link>http://www.medworm.com/index.php?rid=3433033&amp;cid=t_150052_122_f&amp;fid=34755&amp;url=http%3A%2F%2Fneuropsychological.blogspot.com%2F2010%2F04%2Fneuropsychology-abstract-of-day.html</link>
            <description>CONCLUSION: There are spontaneous recovery of post-stroke aphasia within 3 months. Donepezil may facilitate the recovery in spontaneous speech, comprehension, repetition, and naming functions.PMID: 20356506 [PubMed - in process] (Source: BrainBlog)</description>
            <author>BrainBlog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3433033</comments>
            <pubDate>Fri, 02 Apr 2010 14:58:00 +0100</pubDate>
            <guid isPermaLink="false">3433033</guid>        </item>
        <item>
            <title>Neuropsychology Abstract of the Day: Donepezil, MCI, and AD</title>
            <link>http://www.medworm.com/index.php?rid=2667554&amp;cid=t_150052_122_f&amp;fid=34755&amp;url=http%3A%2F%2Fneuropsychological.blogspot.com%2F2009%2F08%2Fneuropsychology-abstract-of-day.html</link>
            <description>Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL &amp; Alzheimer's Disease Cooperative Study Group. (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 72(24):, 2115-2121.Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.OBJECTIVE: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship. METHODS: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study drug trial of donepezil and vitamin E. Beck Depression Inventory (BDI) was used to...</description>
            <author>BrainBlog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2667554</comments>
            <pubDate>Mon, 03 Aug 2009 17:14:00 +0100</pubDate>
            <guid isPermaLink="false">2667554</guid>        </item>
        <item>
            <title>Eisai’s Patents on Alzheimer’s Drug Aricept Expires in 2010 Price to Drop</title>
            <link>http://www.medworm.com/index.php?rid=2580448&amp;cid=t_150052_137_f&amp;fid=35426&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2Fo_U81ruUkno%2Feisais-patents-on-alzheimers-drug.html</link>
            <description>For those of you paying around $166 a month for Aricept there is good news coming soon. The patent for Aricept expires in November, 2010.I would expect the price of Aricept to fall fast once the patent expires.When a patent expires, a single generic drug manufacturer usually gets the competitive edge to manufacture and sell the drug for the first six months. After this six month period of exclusivity, any approved generic manufacturer can jump in and start manufacturing and selling the drug.I would expect the cost of Aricept to plunge to $20 a month in 2011. There should be some good healthy competition in the Aricept market.I remember when Zocor (Simvastatin) went generic. The drug quickly fell from around $120 a month to $20. Now that there is healthy competition it sells around $10. Gue...</description>
            <author>Alzheimer's Reading Room, The</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2580448</comments>
            <pubDate>Tue, 07 Jul 2009 17:12:03 +0100</pubDate>
            <guid isPermaLink="false">2580448</guid>        </item>
        <item>
            <title>Dimebon Connection Study Complete, Additional Phase 3 Trials Still Open</title>
            <link>http://www.medworm.com/index.php?rid=2474102&amp;cid=t_150052_137_f&amp;fid=35426&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FWFyNFlGabYc%2Fdimebon-connection-study-complete.html</link>
            <description>Medivation, Inc. (MDVN) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's disease.The following Dimebon Clinical Phase Three Clinical Trials are open to new participants or scheduled to open.A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's DiseaseIf on existing anti-dementia therapy, have been on a stable dose of anti-dementia therapy (cholinesterase inhibitors and/or memantine) for at least 60 days prior to dosing in study.If not taking existing anti-dementia therapy, have not received therapy with cholinesterase inhibitors and/or memantine within 60 days prior to dosing i...</description>
            <author>Alzheimer's Reading Room, The</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2474102</comments>
            <pubDate>Fri, 12 Jun 2009 00:15:28 +0100</pubDate>
            <guid isPermaLink="false">2474102</guid>        </item>
        <item>
            <title>Alzheimer's Disease: Treatment Directions</title>
            <link>http://www.medworm.com/index.php?rid=1354434&amp;cid=t_150052_122_f&amp;fid=36582&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FSharpBrains%2F%7E3%2F265415184%2F</link>
            <description>Last year, Jeffrey Gonce, a Psychology teacher at Red Land High School (West Shore School District, PA) asked his students to &amp;quot;complete a project describing a recent brain (or genetic) study that affects behavior.&amp;quot; The students could opt to post their articles online, and Jeffrey was kind enough to send us a link to read the results. We enjoyed reading them all, and published in our blog this beautiful essay, titled &amp;quot;Tis better to give than receive&amp;quot;, written by Alexandra, which  was subsequently included in a number of neuroscience an psychology blogs. Earlier this year we highlighted this piece on Musical training as mental exercise for cognitive performance, written by Megan.
This quarter, Jeffrey also sent us his students' essays, and we are going to recognize and p...</description>
            <author>SharpBrains</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1354434</comments>
            <pubDate>Mon, 07 Apr 2008 04:18:26 +0100</pubDate>
            <guid isPermaLink="false">1354434</guid>        </item>
        <item>
            <title>Donepezil Ineffective at Calming Alzheimer's Agitation</title>
            <link>http://www.medworm.com/index.php?rid=927914&amp;cid=t_150052_97_f&amp;fid=35050&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F165359278%2Fdonepezil_ineffective_at_calmi.html</link>
            <description>After a 12-week trial it was found that Alzheimer&amp;#39;s patients with significant agitation experienced no change when compared to patients given a placebo reported Robert J. Howard, M.R.C.Psych., of Kings College London, and colleagues.While previous studies had show some effect in the effectiveness of cholinesterase inhibitors any positive effect has been small. There was however, a small improvement in cognitive function among patients taking Aricept, brand name of donepezil. William Thies, vice president of medical and scientific relations at the Alzheimer&amp;#39;s Association, warns that completely writing off the drug is foolhardy. More research is needed because it is possible that cholinesterase inhibitors may delay the onset of agitation.The Alzheimer&amp;#39;s Assosication has the lates...</description>
            <author>PharmaGazette</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=927914</comments>
            <pubDate>Thu, 04 Oct 2007 20:30:18 +0100</pubDate>
            <guid isPermaLink="false">927914</guid>        </item>
    </channel>
</rss>

